Literature DB >> 17053362

Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity.

Jason D Barbour1, Frederick M Hecht, Susan J Little, Martin Markowitz, Eric S Daar, Anthony D Kelleher, Jean-Pierre Routy, Thomas B Campbell, Eric S Rosenberg, Mark R Segal, Jodi Weidler, Robert M Grant.   

Abstract

We sought to determine whether pretreatment low pol replication capacity (polRC) is associated with CD4 T-cell count gains during antiretroviral therapy (ART). Patients were recruited at north American and Australian sites. Viral polRC was measured before starting ART in all subjects. We examined 243 individuals for a median 260 days after initiating ART. Low baseline polRC was associated with greater CD4 T-cell gains independent of virological responses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17053362     DOI: 10.1097/01.aids.0000247583.38943.95

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  3 in total

Review 1.  Clinical significance of human immunodeficiency virus type 1 replication fitness.

Authors:  Carrie Dykes; Lisa M Demeter
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

2.  Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects.

Authors:  Gail Skowron; John G Spritzler; Jodi Weidler; Gregory K Robbins; Victoria A Johnson; Ellen S Chan; David M Asmuth; Rajesh T Gandhi; Yolanda Lie; Michael Bates; Richard B Pollard
Journal:  J Acquir Immune Defic Syndr       Date:  2009-03-01       Impact factor: 3.731

3.  A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells.

Authors:  Audrey E Rindler; Herbert Kuster; Kathrin Neumann; Christine Leemann; Dominique L Braun; Karin J Metzner; Huldrych F Günthard
Journal:  Viruses       Date:  2021-03-04       Impact factor: 5.048

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.